• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors

    12/2/25 4:14:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email

    Pursuing Board Changes to Restore Investor Confidence and Ensure Integrity of Ongoing Sale Process

    Broadwood Seeks to Remove the Directors Most Responsible for the Flawed Sale Process: Board Chair Elizabeth Yeu, CEO Stephen Farrell, and Compensation Committee Chair Arthur Butcher

    Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today announced that it is well along in the multi-step and time-consuming process that is required to call a Special Meeting of Shareholders (the "Special Meeting") at STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to remove three directors from the Company's Board of Directors (the "Board"). Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to oppose the current agreement to sell the Company to Alcon Inc. ("Alcon") (NYSE:ALC), and believes changes to STAAR's Board are needed to restore investor confidence in the Board's decision making and the sale process.

    At the Special Meeting, Broadwood intends to seek the removal of the three incumbent directors it believes are most responsible for incentivizing, facilitating, and promoting the sale of the Company to Alcon at the wrong time, after a flawed process, and at an inadequate price:

    • Elizabeth Yeu, STAAR's Board Chair, whose close and longstanding relationship with Alcon — which does not appear to have been disclosed to the full Board or to shareholders in a timely manner — may have caused her to ignore inbound interest from another prospective acquirer and, in so doing, irredeemably compromised the sale process;
    • Stephen Farrell, STAAR's CEO, who, having served for only a few months, stands to receive $24 million if the proposed transaction closes, and therefore, in our view, has a powerful incentive to mislead shareholders about STAAR's business and prospects to justify a sale of the Company and preserve his outsized payout (and who, like Yeu, failed to inform the full Board and shareholders of interest from another prospective acquirer); and
    • Arthur Butcher, Chair of the Board's Compensation Committee, who, in our view, bears primary responsibility for the egregious "golden parachute" compensation to STAAR's executives that is nearly twice as high, relative to the implied equity value, as the average amount paid in other M&A transactions in 2025—despite the fact that the average tenure of the STAAR executives is less than two years.

    Neal C. Bradsher, Founder and President of Broadwood, said:

    "By agreeing to — and recklessly persisting with — a deeply flawed transaction that has drawn overwhelming opposition from shareholders and all three major proxy advisory firms, the Board has, in our view, demonstrated its lack of fidelity to the interests of shareholders and other stakeholders.

    As STAAR's largest shareholder, we have been urging the Board for weeks to strengthen its composition by appointing new directors with the independence, expertise, and shareholder alignment necessary to steward the Company responsibly and restore investor trust. The Board should surely understand that, among other things, the credibility of this thrice-delayed vote and belatedly re-engineered sale process would benefit greatly from the oversight of new directors. We anticipate that a refreshed Board would consider, among other matters, how to run a full, fair, independent, and open strategic alternatives process to maximize value that is untainted by the process issues and conflicts of interest that afflicted this proposed transaction with Alcon.

    Unfortunately, the Board ignored these calls to action, and STAAR's future remains in the hands of the same individuals who designed and executed a flawed sale process. Accordingly, we have been engaged in the byzantine process required by STAAR to call the Special Meeting to remove those directors who, in our view, are most responsible for orchestrating and perpetuating this misbegotten proposed transaction. Broadwood is not seeking, and has never sought, control of STAAR. Shareholders deserve a board that truly represents them.

    We believe Board change is urgently needed. We urge STAAR's Board to respect the rights of shareholders by refraining from any gamesmanship or defensive maneuvers and to hold without delay the Special Meeting for which we are calling. It is time for the Board to listen to shareholders' voices so that STAAR can finally realize its full potential."

    Shareholders can find additional information at www.LetSTAARShine.com.

    About Broadwood

    Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.

    Certain Information Concerning the Participants

    Special Meeting of Shareholders Originally Scheduled for October 23, 2025

    Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the "Participants") are participants in the solicitation of proxies from the shareholders of the Company in connection with the special meeting of shareholders originally scheduled for October 23, 2025 and most recently postponed to be held on December 19, 2025 (including any further adjournments, postponements, reschedulings or continuations thereof, the "Proposed Merger Special Meeting"). The Participants have filed a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company's shareholders for the Proposed Merger Special Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE PROPOSED MERGER SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Special Meeting of Shareholders to Remove Members of the Board

    The Participants also intend to file a definitive proxy statement and an accompanying GREEN Proxy Card with the SEC to be used to solicit proxies with respect to removing members of the Board and any other proposals that may come before a future and yet to be called or otherwise scheduled special meeting of shareholders (including any adjournments, postponements, reschedulings or continuations thereof, the "Shareholder Meeting"). The Shareholder Meeting will be separate, distinct and unrelated to the Proposed Merger Special Meeting, and the Participants believe that the Shareholder Meeting will have no effect on the outcome of the Proposed Merger Special Meeting. The Participants do not believe that there is any lawful reason that would prevent or prohibit the Participants from calling the Shareholder Meeting, regardless of the outcome of the shareholder vote at the Proposed Merger Special Meeting, and do not make any representation related to whether the Company may contest, or otherwise challenge, the Participants' ability to call the Shareholder Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SHAREHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on November 21, 2025 and is available here.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251202015519/en/

    Investor Contacts

    John Ferguson / Joseph Mills

    Saratoga Proxy Consulting LLC

    [email protected]

    [email protected]

    (212) 257-1311

    (888) 368-0379

    Media Contacts

    Scott Deveau / Jeremy Jacobs

    August Strategic Communications

    [email protected]

    (323) 892-5562

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC
    $STAA

    CompanyDatePrice TargetRatingAnalyst
    Alcon Inc.
    $ALC
    2/26/2026$97.00Equal Weight → Overweight
    Wells Fargo
    STAAR Surgical Company
    $STAA
    2/3/2026$26.00Neutral
    Wedbush
    Alcon Inc.
    $ALC
    1/30/2026Mkt Perform
    William Blair
    Alcon Inc.
    $ALC
    1/20/2026Hold → Buy
    Deutsche Bank
    STAAR Surgical Company
    $STAA
    1/16/2026$13.00Underweight
    Morgan Stanley
    Alcon Inc.
    $ALC
    1/9/2026Buy → Hold
    Stifel
    Alcon Inc.
    $ALC
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    Alcon Inc.
    $ALC
    8/21/2025Overweight → Neutral
    Analyst
    More analyst ratings

    $ALC
    $STAA
    SEC Filings

    View All

    STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    3/3/26 4:05:29 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 10-K filed by STAAR Surgical Company

    10-K - STAAR SURGICAL CO (0000718937) (Filer)

    3/3/26 3:58:10 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    2/24/26 4:44:18 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00

    2/26/26 7:10:22 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Wedbush initiated coverage on STAAR Surgical with a new price target

    Wedbush initiated coverage of STAAR Surgical with a rating of Neutral and set a new price target of $26.00

    2/3/26 8:08:13 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    William Blair initiated coverage on Alcon

    William Blair initiated coverage of Alcon with a rating of Mkt Perform

    1/30/26 6:43:20 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim Co-CEO and Pres. & COO Foust Warren converted options into 37,500 shares, increasing direct ownership by 144% to 63,588 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:16 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:17 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Chief Development Officer Michna Magda converted options into 23,773 shares and covered exercise/tax liability with 8,529 shares, increasing direct ownership by 105% to 29,668 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:14 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/13/26 7:59:59 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $606,138 worth of shares (27,485 units at $22.05) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/13/26 9:30:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $8,817,664 worth of shares (406,653 units at $21.68) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/8/26 7:31:31 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by d

    3/16/26 4:57:00 PM ET
    $ALC
    $LNSR
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    STAAR Surgical Issues Shareholder Letter

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR's results release can be found here: https://investors.staar.com/news-and-events/press-releases. Fellow Shareholders, This past month marked an important transition for our company as we stepped into the roles of Interim co-Chief Executive Officers. We are honored by the Board's confidence and deeply grateful for the dedication of our employees, the loyalty of our customers, and the opportunity to serve you—our shareholders. It is with great pleasure

    3/3/26 4:02:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

    Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/new

    3/3/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

    Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.

    2/2/26 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

    Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%

    1/15/26 8:30:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Financials

    Live finance-specific insights

    View All

    STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

    Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/new

    3/3/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales

    Fourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency1 (cc), versus fourth-quarter 2024 Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS2 of $0.78 Generated $2.3 billion of cash from operations and $1.7 billion of free cash flow3 in full-year 2025 Returned $848 million to shareholders through share repurchases and dividends Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant curren

    2/24/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast Date: Tuesday, March 3, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd Topics on the c

    2/23/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care